About Rheincell Therapeutics
Rheincell Therapeutics is a Healthcare company based in Langenfeld (Germany) founded in 2017, and was acquired by Catalent in June 2021. IPS cells are developed for therapeutics to prevent immune rejection. Its chief executive, as recorded, is Jurgen Weisser. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is RHEINCELL Therapeutics GmbH.
Company details
Rheincell Therapeutics was founded in 2017 in Langenfeld, Germany, within the biotechnology sector. Focus is placed on induced pluripotent stem (iPS) cells as a platform for cell-based therapies. A master cell bank is maintained to serve as starting material for various therapeutic applications, aiming to reduce immune rejection in recipients. Operations center on creating scalable sources for iPSC-derived treatments.
- Headquarters Langenfeld, Germany
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rheincell.de
- Social LinkedIn
- Acquired by Catalent (Jun 2021)
- Legal Name Rheincell Therapeutics Gmbh
Investors in Rheincell Therapeutics
Rheincell Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Catalent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CDMO offering drug and biologics development services | 2007 | catalent.com | Somerset, United States |
Investor details for Rheincell Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rheincell Therapeutics
1 people are tracked at Rheincell Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jurgen Weisser | CEO | Leadership |
Complete people profiles for Rheincell Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rheincell Therapeutics
2 dated milestones of Rheincell Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Rheincell Therapeutics is founded.
- Exit Acquired by Catalent.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rheincell Therapeutics
Complete news archive for Rheincell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rheincell Therapeutics
Rheincell Therapeutics was founded in 2017.
Rheincell Therapeutics is headquartered in Langenfeld, Germany. It is registered at Langenfeld, North Rhine-westphalia, Germany.
Jurgen Weisser is the CEO of Rheincell Therapeutics, as recorded in our data.
Rheincell Therapeutics was founded in 2017 in Langenfeld, Germany, within the biotechnology sector. Focus is placed on induced pluripotent stem (iPS) cells as a platform for cell-based therapies. A master cell bank is maintained to serve as starting material for various therapeutic applications, aiming to reduce immune rejection in recipients. Operations center on creating scalable sources for iPSC-derived treatments.
Rheincell Therapeutics has 1 investor. Key investors include Catalent.
Rheincell Therapeutics operates through Rheincell Therapeutics Gmbh.
Yes. Rheincell Therapeutics was acquired by Catalent in June 2021.